Vanda Pharmaceuticals Inc. (VNDA)
- Sector
- Biotechnology
- Last price
- $4.22
- As of
Kresmion compiles this page from VNDA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Vanda Pharmaceuticals Inc. (VNDA): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-06.
See the full VNDA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VNDA on one page. Preview it with sample data, then open it live with a free account.
Preview the VNDA dossierActive signals for VNDA
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +255% to VNDA (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +3673% to VNDA (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +93% to VNDA (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 73.5%, EPS $-1.04 vs $-0.5993 estimate
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +163% to VNDA (2026Q1)
FREE, NO ACCOUNT
Every signal on VNDA, as it fires
You are seeing 5 of 9 signals recorded on VNDA since 2026-05-17.
The five above landed across 3 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in VNDA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 921659108 · 2026Q2 | $21.1M | 0.03% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 921659108 · 2026Q2 | $9.8M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 921659108 · 2026Q2 | $8.3M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 921659108 · 2026Q2 | $4.6M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 921659108 · 2026Q2 | $1.9M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, VNDA
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
VNDA against its peers
VNDA's operating margin of -70.0% ranks in the 61st percentile of 13 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | VNDA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 216M USD | 22.2M USD | 91 | 16 |
| Operating margin | -70.0% | -340.4% | 61 | 13 |
| Net margin | -102.0% | -225.6% | 54 | 13 |
| Return on equity | -67.4% | -33.1% | 21 | 20 |
| 1 year | -19.3% | -16.8% | 45 | 20 |
Peers (22): NAUT, BBOT, ABEO, XFOR, PALI, BCYC, IPSC, RCKT, IKT, EVMN, ANIK, QTTB, NWBO, ACIU, PRLD, SABS, EYPT, ZNTL, KROS, LXEO, IMRX, AGEN. Left out: VOGX (no annual filing), VCRE (no annual filing), CUVL (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (VNDA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow VNDA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to VNDA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.